TGTX Q2 2019 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38,000+0.0% YoY

Gross Profit

$38,000100.0% margin

Operating Income

-$36M-93536.8% margin

Net Income

-$36M-95297.4% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$36M

Free Cash Flow

-$36M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$107M

Total Liabilities

$93M

Stockholders' Equity

$13M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38,000	$38,000	+0.0%
Gross Profit	$38,000	$38,000	+0.0%
Operating Income	-$36M	-$44M	+19.8%
Net Income	-$36M	-$44M	+18.0%